| 2023-06-01 |
复牌提示：
2023-05-31 19:51:49 停牌，复牌日期 2023-06-02 00:00:01
|
| 2023-06-01 |
详情>>
内部人交易：
Cardama Alfonso Quintas等共交易5笔
|
| 2023-05-11 |
详情>>
股本变动：
变动后总股本3926.17万股
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-1.03美元,归母净利润-4039.9万美元,同比去年增长-38.72%
|
| 2023-04-20 |
股东大会：
将于2023-05-30召开股东大会
会议内容 ▼▲
- 1.To consider and vote on a proposal to adopt the Agreement and Plan of Merger, dated as of March 5, 2023 (as it may be amended from time to time, the “merger agreement”) by and among TCR2, Adaptimmune Therapeutics plc (“Adaptimmune”) and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Adaptimmune (“Merger Sub”), pursuant to which Merger Sub will merge with and into TCR2 (the “merger”), with TCR2 surviving the merger as a wholly-owned direct subsidiary of CM Intermediate Sub II, Inc., a Delaware corporation and subsidiary of Adaptimmune (the “merger proposal”);
2.To consider and vote on a proposal to approve the adjournment or postponement of the TCR2 special meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the TCR2 special meeting to approve the merger proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to TCR2 stockholders (the “TCR2 adjournment proposal”).
|
| 2023-03-23 |
详情>>
业绩披露：
2022年年报每股收益-3.93美元,归母净利润-1.52亿美元,同比去年增长-52.12%
|
| 2022-11-08 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-2.37美元,归母净利润-9131.7万美元,同比去年增长-26.71%
|
| 2022-09-01 |
股东大会：
将于2022-10-14召开股东大会
会议内容 ▼▲
- 1.To elect two Class I director nominees to our board of directors (“Board of Directors”), to serve until the Company’s 2025 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal;
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2022-08-08 |
详情>>
业绩披露：
2022年中报每股收益-1.58美元,归母净利润-6072.3万美元,同比去年增长-32.51%
|
| 2022-05-12 |
详情>>
业绩披露：
2022年一季报每股收益-0.76美元,归母净利润-2912.2万美元,同比去年增长-35.38%
|
| 2022-03-22 |
详情>>
业绩披露：
2021年年报每股收益-2.63美元,归母净利润-9980.7万美元,同比去年增长-48.69%
|
| 2021-11-10 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-1.91美元,归母净利润-7206.8万美元,同比去年增长-48.07%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-09-03 |
股东大会：
将于2021-10-22召开股东大会
会议内容 ▼▲
- 1.To elect three Class III director nominees to our board of directors, to serve until the Company’s 2024 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal.
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2021-08-05 |
详情>>
业绩披露：
2021年中报每股收益-1.22美元,归母净利润-4582.4万美元,同比去年增长-44.32%
|
| 2021-05-13 |
详情>>
业绩披露：
2021年一季报每股收益-0.58美元,归母净利润-2151.2万美元,同比去年增长-38.73%
|
| 2021-03-16 |
详情>>
业绩披露：
2020年年报每股收益-2.4美元,归母净利润-6712.4万美元,同比去年增长31.15%
|
| 2020-08-14 |
股东大会：
将于2020-10-01召开股东大会
会议内容 ▼▲
- 1.To elect three Class II director nominees to our board of directors, to serve until the Company’s 2023 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal;
2.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2019-08-28 |
股东大会：
将于2019-10-10召开股东大会
会议内容 ▼▲
- 1.To elect a class I director nominee to our board of directors, to serve until the Company’s 2022 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal;
2.To approve a proposed amendment to the TCR2 Therapeutics Inc. 2018 Stock Option and Incentive Plan;
3.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|